View Older Stories
-
FDA grants priority review to AstraZeneca's Imfinzi combination for bladder cancer
-
AstraZeneca to present gefurulimab trial data at neurology meetings
-
AstraZeneca extends Young Health Programme with $100m total investment
-
AstraZeneca's Trixeo gets EU approval for asthma treatment
-
Roche obesity drug shows 15.5% weight loss in diabetes trial
-
AstraZeneca's Klygefa receives positive EU approval recommendation
-
FDA grants priority review to AstraZeneca's efzimfotase alfa for bone disease
-
Enhertu approved for NHS use in England for breast cancer patients
-
Buy the pullback in this large pharma stock: UBS
-
Weakness in this biotech stock is a buying opportunity: Stifel
-
Deutsche Bank Upgrades AstraZeneca (AZN:LN) (AZN) to Hold
-
Enhertu beats standard care in lung cancer trial on key metric
-
AstraZeneca's Tagrisso shows 47% death risk reduction at eight years
-
AstraZeneca's camizestrant fails primary endpoint in breast cancer trial
-
RBC Capital Starts AstraZeneca (AZN:LN) (AZN) at Outperform
-
Imfinzi plus tarlatamab shows survival gains in lung cancer trial
-
AstraZeneca COPD drug tozorakimab cuts exacerbations in Phase III trials
-
FDA grants accelerated approval to AstraZeneca's camizestrant combo
-
FDA approves AstraZeneca breast cancer drug Etcamah via accelerated path
-
EU approves Enhertu combo for first-line HER2-positive breast cancer
-
AstraZeneca acquires worldwide rights to lung cancer drug Zegfrovy
-
AstraZeneca's Tagrisso combo shows Phase III benefit in lung cancer
-
AstraZeneca's Tezspire meets endpoints in esophagitis trial
-
AstraZeneca halts Phase III lung cancer trial after data review
-
AstraZeneca's Tagrisso and Orpathys combo meets Phase III goals
-
Morgan Stanley analysts visit National Resilience facility in Ohio, clients include LLY and AZN
-
AZN spikes 6% after report it denies AstraZeneca-BMS merger talks
-
'No Discussions' Over Astrazeneca-Bristol Myers Deal, Senior Source Says - Reuters
-
SOPHiA Genetics and AstraZeneca team up on two cancer diagnostics
-
Bristol-Myers Squibb and AstraZeneca said to discuss megamerger - can it happen?
-
AstraZeneca reviews potential Bristol Myers deal, Barclays comments
-
AstraZeneca (AZN) call put ratio 1.7 calls to 1 put into share price lower before the bell
-
Bernstein says risk-reward is positively skewed for this pharma stock
-
EU approves AstraZeneca and Daiichi Sankyo's Datroway for breast cancer
-
AstraZeneca says adjusting drug pricing over Trump policies
-
AstraZeneca drug shows survival benefit in gastric cancer trial
-
AstraZeneca (AZN) Tops Q2 EPS by 14c
-
AstraZeneca's Ultomiris misses primary endpoint in adult HSCT-TMA trial
-
AstraZeneca drug shows survival benefit in gastric cancer trial
-
AstraZeneca (AZN) Q2 earnings preview
-
Enhertu combination gets EU approval recommendation for breast cancer
-
AstraZeneca's Trixeo receives EU recommendation for asthma treatment
-
Alnylam Pharmaceuticals (ALNY) PT Raised to $485 at H.C. Wainwright
-
AstraZeneca licenses sunvozertinib from Dizal for $600M upfront
-
AstraZeneca stock dips as HSBC downgrades stock on 'tough path ahead'
-
BridgeBio Pharma (BBIO) PT Raised to $120 at H.C. Wainwright
-
HSBC Downgrades AstraZeneca (AZN:LN) (AZN) to Hold
-
Bernstein keeps telling clients to buy this pharma stock
-
Buy the pullback in this major pharma stock: Bernstein
-
AstraZeneca (AZN) call put ratio 1.9 calls to 1 put with a focus on July 180 and 190 calls

